Christopher Ta, MD

Clinical Focus

• Ophthalmology

Administrative Appointments

• Residency Program Director, Ophthalmology , (2003– present )

Professional Education

• Board Certification: Ophthalmology, American Board of Ophthalmology (2000)
• Univ Of Texas Southwestern (1999) TX
• SUMC - Graduate Medical Education (1998) CA
• Kaiser Foundation Hospital-Oakland (1995) CA
• University of Minnesota (1994) MN
• BA, University of Minnesota Physiology (1990)
• MD, University of Minnesota Medicine (1994)
• Residency, Stanford University Ophthalmology (1998)
• Fellowship, University of Texas, Dallas Cornea (1999)

Graduate & Fellowship Program Affiliations

• Ophthalmology

Web Site Links

• Christopher Ta Clinical Website

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: Lux, Vistakon

Research Interests

Dr. Ta is the PI for two major research projects:
(1) Development of an artificial cornea
(2) Ocular microbiology - prevention and treatment of ocular infectious diseases.

Clinical Trials

• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Recruiting

Publications

• Prospective study of risk factors for conjunctival bacterial contamination in patients undergoing intraocular surgery. Miño De Kaspar H,  Ta CN, Froehlich SJ, Schaller UC, Engelbert M, Klauss V, Kampik A.  Eur J Ophthalmol.  2009 Sep-Oct; 19 (5): 717-22
• Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria. He L,  Ta CN, Hu N, Sinnar S, Miño de Kaspar H.  J Ocul Pharmacol Ther.  2009; 25 (4): 373-8
• One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus. He L,  Ta CN, Miño de Kaspar H.  J Cataract Refract Surg.  2009; 35 (10): 1715-8
• In vitro antibiotic susceptibility of preoperative normal conjunctival bacteria. Ta CN,  He L, Mino de Kaspar H.  Eye (Lond).  2009; 23 (3): 559-60
• Bioactive interpenetrating polymer network hydrogels that support corneal epithelial wound healing. Myung D,  Farooqui N, Zheng LL, Koh W, Gupta S, Bakri A, Noolandi J, Cochran JR, Frank CW, Ta CN.  J Biomed Mater Res A.  2009; 90 (1): 70-81
• Development of hydrogel-based keratoprostheses: a materials perspective. Myung D,  Duhamel PE, Cochran JR, Noolandi J, Ta CN, Frank CW.  Biotechnol Prog.  2008 May-Jun; 24 (3): 735-41
• Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. de Caro JJ,  Ta CN, Ho HK, Cabael L, Hu N, Sanislo SR, Blumenkranz MS, Moshfeghi DM, Jack R, de Kaspar HM.  Retina.  2008; 28 (6): 877-83
• Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application. Ta CN,  Chan I, Dhatt HS, Paterno J, Fisher E, Singh K, Montague A, Egbert PR, Cockerham G, Kaspar HM.  J Ocul Pharmacol Ther.  2008; 24 (4): 427-31
• A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Miño de Kaspar H,  Kreutzer TC, Aguirre-Romo I, Ta CN, Dudichum J, Bayrhof M, Klauss V, Kampik A.  Am J Ophthalmol.  2008; 145 (1): 136-142
• Glucose-permeable interpenetrating polymer network hydrogels for corneal implant applications: a pilot study. Myung D,  Farooqui N, Waters D, Schaber S, Koh W, Carrasco M, Noolandi J, Frank CW, Ta CN.  Curr Eye Res.  2008; 33 (1): 29-43
• Comparison of one-day versus one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora. Moss JM,  Nguyen D, Liu YI, Singh K, Montague A, Egbert PR, Kaspar HM, Ta CN.  Ophthalmology.  2008; 115 (11): 2013-6
• Effects of intravitreal corticosteroid in the treatment of Staphylococcus aureus-induced experimental endophthalmitis. De Kaspar HM,  Ta CN, Engelbert M, Mette M, Thiel M, Kampik A.  Retina.  2008; 28 (2): 326-32
• Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. Ta CN,  Sinnar S, He L, Myung D, Miño De Kaspar H.  Eur J Ophthalmol.  2007 Sep-Oct; 17 (5): 689-95
• Aspergillus fumigatus keratitis following laser in situ keratomileusis. Sun Y,  Jain A, Ta CN.  J Cataract Refract Surg.  2007; 33 (10): 1806-7
• Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct. Myung D,  Koh W, Bakri A, Zhang F, Marshall A, Ko J, Noolandi J, Carrasco M, Cochran JR, Frank CW, Ta CN.  Biomed Microdevices.  2007; 9 (6): 911-22
• Topical antibiotic prophylaxis in intraocular injections. Ta CN,  Arch Ophthalmol.  2007; 125 (7): 972-4
• [The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva] Koss MJ,  Eder M, Blumenkranz MS, Klauss V, Ta CN, de Kaspar HM.  Ophthalmologe.  2007; 104 (1): 21-7
• Prospective study demonstrating the efficacy of combined preoperative three-day application of antibiotics and povidone-iodine irrigation. Ta CN,  Lin RC, Singh G, Miño de Kaspar H.  Ann Ophthalmol (Skokie).  2007; 39 (4): 313-7
• Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. Ta CN,  He L, Nguyen E, De Kaspar HM.  Eur J Ophthalmol.  2006 May-Jun; 16 (3): 359-64
• Glucose permeability of human, bovine, and porcine corneas in vitro. Myung D,  Derr K, Huie P, Noolandi J, Ta KP, Ta CN.  Ophthalmic Res.  2006; 38 (3): 158-63
• Endophthalmitis prophylaxis. Ou JI,  Ta CN.  Ophthalmol Clin North Am.  2006; 19 (4): 449-56
• Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis. Sonego-Krone S,  Sanchez-Di Martino D, Ayala-Lugo R, Torres-Alvariza G, Ta CN, Barbosa L, de Kaspar HM.  Graefes Arch Clin Exp Ophthalmol.  2006; 244 (7): 782-7
• Use of rapid antibiotic susceptibility testing in bacterial endophthalmitis. de Kaspar HM,  Kreutzer TC, Ta CN, Kampik A.  Retina.  2005 Apr-May; 25 (3): 386-7; author reply 387-8
• Antibiotic susceptibility of preoperative normal conjunctival bacteria. Miño de Kaspar H,  Koss MJ, He L, Blumenkranz MS, Ta CN.  Am J Ophthalmol.  2005; 139 (4): 730-3
• Normal ocular flora in newborns delivered in two hospital centers in Argentina and Paraguay. Eder M,  Fariña N, Sanabria RR, Ta CN, Koss M, Samudio M, Cuevas C, Gines A, Simancas M, Klauss V, Miño de Kaspar H.  Graefes Arch Clin Exp Ophthalmol.  2005; 243 (11): 1098-107
• Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. Miño de Kaspar H,  Chang RT, Singh K, Egbert PR, Blumenkranz MS, Ta CN.  Arch Ophthalmol.  2005; 123 (2): 161-5
• Evolving guidelines for intravitreous injections. Aiello LP,  Brucker AJ, Chang S, Cunningham ET, D'Amico DJ, Flynn HW, Grillone LR, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, Ta C, Trese MT.  Retina.  2004; 24 (5 Suppl): S3-19
• Epidemiological characteristics of microbiological results on patients with infectious corneal ulcers: a 13-year survey in Paraguay. Laspina F,  Samudio M, Cibils D, Ta CN, Fariña N, Sanabria R, Klauss V, Miño de Kaspar H.  Graefes Arch Clin Exp Ophthalmol.  2004; 242 (3): 204-9
• Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis. Engelbert M,  Miño de Kaspar H, Thiel M, Grasbon T, Ta CN, Schulze-Schwering M, Klauss V, Kampik A.  Graefes Arch Clin Exp Ophthalmol.  2004; 242 (4): 313-20
• Minimizing the risk of endophthalmitis following intravitreous injections. Ta CN,  Retina.  2004; 24 (5): 699-705
• Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. de Kaspar HM,  Kreidl KO, Singh K, Ta CN.  J Glaucoma.  2004; 13 (6): 507-9
• Three-day application of topical ofloxacin reduces the contamination rate of microsurgical knives in cataract surgery: a prospective randomized study. De Kaspar HM,  Chang RT, Shriver EM, Singh K, Egbert PR, Blumenkranz MS, Ta CN.  Ophthalmology.  2004; 111 (7): 1352-5
• The challenge of determining aqueous contamination rate in anterior segment intraocular surgery. Ta CN,  Egbert PR, Singh K, Blumenkranz MS, de Kaspar HM.  Am J Ophthalmol.  2004; 137 (4): 662-7
• Intravenous treatment of experimental Staphylococcus aureus endophthalmitis: imipenem versus the combination of ceftazidime and amikacin. Engelbert M,  Miño de Kaspar H, Mette M, Thiel M, Ta CN, Grasbon T, Schulze-Schwering M, Klauss V, Kampik A.  Graefes Arch Clin Exp Ophthalmol.  2003; 241 (12): 1029-36
• Preoperative ofloxacin: author reply Ta CN,  Egbert PR, Singh K, Blumenkranz MS, Mino de Kaspar H.  Ophthalmology.  2003; 110 (12): 2431-1432
• Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Ta CN,  Shine WE, McCulley JP, Pandya A, Trattler W, Norbury JW.  Cornea.  2003; 22 (6): 545-8
• Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ta CN,  Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, Miño de Kaspar H.  Ophthalmology.  2003; 110 (10): 1946-51
• Risk factors for antibiotic-resistant conjunctival bacterial flora in patients undergoing intraocular surgery. Miño de Kaspar H,  Shriver EM, Nguyen EV, Egbert PR, Singh K, Blumenkranz MS, Ta CN.  Graefes Arch Clin Exp Ophthalmol.  2003; 241 (9): 730-3
• Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ta CN,  Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño De Kaspar H.  Ophthalmology.  2002; 109 (11): 2036-40; discussion 2040-1
• Bilateral Mycobacterium abscessus keratitis after laser in situ keratomileusis. Giaconi J,  Pham R, Ta CN.  J Cataract Refract Surg.  2002; 28 (5): 887-90
• Rapid direct antibiotic susceptibility testing in endophthalmitis. Miño de Kaspar H,  Neubauer AS, Molnar A, Hoepfner AS, Ta CN, Grasbon T, Engelbert M, Thiel M, Klauss V, Kampik A.  Ophthalmology.  2002; 109 (4): 687-93
• Intravenous imipenem prophylaxis in experimental endophthalmitis. Miño de Kaspar H,  Engelbert M, Thiel M, Grasbon T, Ta CN, Klauss V, Kampik A.  Graefes Arch Clin Exp Ophthalmol.  2002; 240 (7): 557-64
• Nodular scleritis in a patient with pyoderma gangrenosum. Braun MM,  Wong IG, Ta CN.  Arch Ophthalmol.  2002; 120 (12): 1763-5
• Evaluation and management of herpes zoster ophthalmicus. Shaikh S,  Ta CN.  Am Fam Physician.  2002; 66 (9): 1723-30
• Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model. Miño De Kaspar H,  Hoepfner AS, Engelbert M, Thiel M, Ta CN, Mette M, Schulze-Schwering M, Grasbon T, Sesma-Vea B, Casas JM, Iturralde-Goñi R, Klauss V, Kampik A.  Ophthalmology.  2001; 108 (3): 470-8
• Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection. Shaikh S,  Ta C, Basham AA, Mansour S.  Am J Ophthalmol.  2001; 131 (1): 143-5
• Hyphema caused by a metallic intraocular foreign body during magnetic resonance imaging. Ta CN,  Bowman RW.  Am J Ophthalmol.  2000; 129 (4): 533-4
• Constitutive mutations of Agrobacterium tumefaciens transcriptional activator virG. Pazour GJ,  Ta CN, Das A.  J Bacteriol.  1992; 174 (12): 4169-74
• Mutants of Agrobacterium tumefaciens with elevated vir gene expression. Pazour GJ,  Ta CN, Das A.  Proc Natl Acad Sci U S A.  1991; 88 (16): 6941-5